Please use this identifier to cite or link to this item: https://doi.org/10.1155/2015/308574
DC FieldValue
dc.titleStrategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
dc.contributor.authorSubhash, V.V
dc.contributor.authorYeo, M.S
dc.contributor.authorTan, W.L
dc.contributor.authorYong, W.P
dc.date.accessioned2020-09-14T08:19:48Z
dc.date.available2020-09-14T08:19:48Z
dc.date.issued2015
dc.identifier.citationSubhash, V.V, Yeo, M.S, Tan, W.L, Yong, W.P (2015). Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research 2015 : 308574. ScholarBank@NUS Repository. https://doi.org/10.1155/2015/308574
dc.identifier.issn2314-8861
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/176161
dc.description.abstractIn cancer biology, cells and molecules that form the fundamental components of the tumor microenvironment play a major role in tumor initiation, and progression as well as responses to therapy. Therapeutic approaches that would enable and harness the immune system to target tumor cells mark the future of anticancer therapy as it could induce an immunological memory specific to the tumor type and further enhance tumor regression and relapse-free survival in cancer patients. Gastric cancer is one of the leading causes of cancer-related mortalities that has a modest survival benefit from existing treatment options. The advent of immunotherapy presents us with new approaches in gastric cancer treatment where adaptive cell therapies, cancer vaccines, and antibody therapies have all been used with promising outcomes. In this paper, we review the current advances and prospects in the gastric cancer immunotherapy. Special focus is laid on new strategies and clinical trials that attempt to enhance the efficacy of various immunotherapeutic modalities in gastric cancer. © 2015 Vinod Vijay Subhash et al.
dc.sourceUnpaywall 20200831
dc.subjectantineoplastic agent
dc.subjectcancer vaccine
dc.subjectchimeric antigen receptor
dc.subjectcytotoxic T lymphocyte antigen 4
dc.subjectdendritic cell vaccine
dc.subjectdurvalumab
dc.subjectimmunomodulating agent
dc.subjectipilimumab
dc.subjectmpdl 3280a
dc.subjectnivolumab
dc.subjectpembrolizumab
dc.subjectprogrammed death 1 ligand 1
dc.subjectT lymphocyte antigen
dc.subjectticilimumab
dc.subjecttumor antigen
dc.subjectcancer vaccine
dc.subjectadaptive immunity
dc.subjectadoptive immunotherapy
dc.subjectadoptive transfer
dc.subjectcancer immunization
dc.subjectcancer immunotherapy
dc.subjectcytotoxic T lymphocyte
dc.subjecthuman
dc.subjectimmune evasion
dc.subjectimmune response
dc.subjectimmune system
dc.subjectimmunogenicity
dc.subjectimmunosurveillance
dc.subjectinnate immunity
dc.subjectmulticenter study (topic)
dc.subjectnatural killer cell
dc.subjectphase 1 clinical trial (topic)
dc.subjectphase 2 clinical trial (topic)
dc.subjectrandomized controlled trial (topic)
dc.subjectReview
dc.subjectstomach cancer
dc.subjectT lymphocyte
dc.subjecttumor associated leukocyte
dc.subjecttumor microenvironment
dc.subjectclinical trial (topic)
dc.subjectimmunity
dc.subjectimmunological memory
dc.subjectimmunological monitoring
dc.subjectimmunology
dc.subjectimmunotherapy
dc.subjectprocedures
dc.subjectStomach Neoplasms
dc.subjectCancer Vaccines
dc.subjectClinical Trials as Topic
dc.subjectHumans
dc.subjectImmune System Phenomena
dc.subjectImmunologic Memory
dc.subjectImmunotherapy
dc.subjectMonitoring, Immunologic
dc.subjectStomach Neoplasms
dc.subjectTumor Microenvironment
dc.typeReview
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.1155/2015/308574
dc.description.sourcetitleJournal of Immunology Research
dc.description.volume2015
dc.description.page308574
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2015_308574.pdf2.64 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.